ArticleFrontiers in oncology2025
Clinicopathologic characteristics and prognosis of basaloid squamous cell carcinoma of the rectum in comparison with adenocarcinoma: a retrospective cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Basaloid squamous cell carcinoma (BSCC) is a rare histological subtype of rectal cancer. This study aimed to investigate the clinicopathologic features and survival outcomes of primary rectal BSCC and to compare them with those of adenocarcinoma (AD). Methods: Patients diagnosed with rectal BSCC and AD patients were identified from the Surveillance, Epidemiology, and End Results database from 2000 to 2019. Univariable and multivariable Cox regression analyses were performed to identify potential risk factors for survival in BSCC patients. A nomogram was constructed to predict the prognosis of BSCC patients. Results: A total of 257 BSCC and 77,094 AD patients were identified. BSCC patients were more significantly correlated with female gender, early clinical stage, and poor differentiation. Significantly better 5-year overall survival (OS) and cancer-specific survival (CSS) were observed in patients with BSCC than those with AD (OS: 60.4% Conclusion: Patients with rectal BSCC have significantly better survival outcomes than those with rectal AD, with a more early clinical stage. Surgery in combination with chemotherapy is the preferred treatment to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.